Ozempic® Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza® and…
Novo Nordisk announced today the results from two Ozempic® (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: